EXCHANGE TRANSFUSION WITH VS -101: A NEW PEGYLATED-HB DESIGNED TO RESTORE PERFUSION AND INCREASE O 2 CARRYING...

Area of Science:

• Biomedical Engineering
• Emergency Medicine
• Resuscitation Science

Background:

• Blood products are standard for hemorrhagic shock but face logistical challenges.
• Alternatives to blood transfusion are crucial for prehospital and widespread use.
• PEGylated hemoglobin-based oxygen carriers offer potential solutions.

Purpose of the Study:

• To evaluate the safety and efficacy of VS-101 in a severe exchange transfusion model.
• To assess VS-101's ability to maintain circulatory function and oxygen delivery.
• To compare VS-101 resuscitation to lactated Ringer's solution (LRS).

Main Methods:

• A 50% isovolemic exchange transfusion model was used in anesthetized Sprague Dawley rats.
• Cardiovascular parameters and interstitial fluid oxygen tension (P ISFo2) were monitored.
• Animals received either VS-101 or LRS at 1 mL/kg/min for 240 minutes.

Main Results:

• VS-101 maintained P ISFo2 and mean arterial pressure (MAP) with only a transient decrease.
• LRS caused a significant drop in P ISFo2 and MAP, leading to 100% mortality.
• VS-101 treated animals survived the full 240-minute observation period without vasoconstriction.

Conclusions:

• VS-101 effectively maintained blood pressure, perfusion, and tissue oxygenation in severe hemorrhagic shock.
• VS-101 demonstrated superior resuscitation effects compared to LRS in this animal model.
• Further research into VS-101 is warranted to support future clinical trials for hemorrhagic shock treatment.